Inosi Therapeutics tackles fibrosis
Fibrosis is a condition associated with many chronic diseases, where tissue damage leads to scarring and loss of organ function. There is a huge unmet need for therapies that can prevent or reverse fibrosis to modify the progress of disease. Monash researchers Prof Siew Chai, Dr Tracey Gaspari, Prof Rob Widdop and Prof Phil Andrews collaborated on a technology to treat fibrosis and a new university spinout company Inosi Therapeutics has been created.
The team at Monash Innovation lead the deal, with investment from the IP Group and BioCurate providing funding and expertise to translate the research outcome as rapidly as possible into much needed new treatments.